New malaria treatments are more effective,
but are those most at risk using them?
NAIROBI, Kenya, April 25, 2008 — As the world works towards rapidly increasing the use of bednets to prevent malaria, some of the countries worst hit by the global malaria pandemic — Benin, Democratic Republic of Congo, Cambodia, Madagascar, Nigeria, Uganda and Zambia — may soon be providing the world with answers to increasing access to prompt and correct use of malaria treatment.
Through a multicountry project called ACTwatch, researchers in each of these countries are working with the national malaria control programs to monitor key indicators of effective malaria treatment in both the public and private sectors. The initiative will be launched this World Malaria Day in Nairobi, Kenya. Over the next five years, ACTwatch, which is funded by the Bill and Melinda Gates Foundation, will measure whether donor financing initiatives have been successful in reducing the price and increasing the use of artemisinin-based combination therapies (ACTs) — the new wonder drugs for treating malaria.
ACTwatch is being implemented by a consortium of partners led by the nongovernmental organization, Population Services International (PSI) in partnership with the London School of Hygiene and Tropical Medicine, United States Pharmacopeia and the market research firm, Nielsen. The project will be carried out in six African countries (Benin, Democratic Republic of Congo, Madagascar, Nigeria, Uganda and Zambia) and two countries in Southeast Asia (Cambodia and one other, yet to be decided upon).
Following the launch, an international coordination meeting will take place in Nairobi between 29th April and 1st May during which all partners, representatives from the study countries and an advisory committee of international malaria experts, will convene to carry out the detailed planning of a series of research studies. These studies will examine the price, availability and quality of different types of antimalarials, in shops and health facilities. Studies will also investigate malaria treatment seeking behavior in the community as well as looking at the impact of government policies on the structure of the antimalarial market in each country. In essence, it will measure what people with malaria use to treat malaria and why. The principal outputs of ACTwatch will be evidence on changes in the availability, affordability and use of ACTs, in all sectors, as well as policy recommendations targeting national and international decision-makers to increase use of ACTs in vulnerable communities.
Over the past two to three years, ACTs have become the malaria treatment of choice and have replaced drugs, such as chloroquine, which have become ineffective due to the emergence of resistant malaria parasites. While ACTs are extremely effective in treating malaria, they are sold for up to 10 times the price of chloroquine. As a result, major donor initiatives, such as the Global Fund to fight AIDS, TB and malaria (GFATM) have provided funds to individual countries to procure ACTs for supply through public health facilities to treat patients sick with malaria.
Although most countries at risk from malaria have at least some supplies of this new wonder drug in public health facilities, almost half of all malaria patients access treatment through shops, where many kinds of antimalarial treatments, of varying quality, can be found. Few shops even stock ACTs because they are so expensive. As a result, most patients continue to buy ineffective malaria treatment because that is all that they can afford. To address this problem, a variety of financing initiatives to subsidize ACTs in the private sector are now either in place or being discussed. The largest of these initiatives (the affordable medicines facility for malaria — AMFm), which has yet to be launched, aims to provide funding to purchase ACTs from qualifying manufacturers so that importers and distributors in malaria affected countries can introduce ACTs into the supply chain for next to nothing. The intended result is that ACTs should be available in shops for roughly the same price as the cheap and ineffective drugs, such as chloroquine. ACTwatch and other antimalarial market monitoring initiatives will measure the extent to which these initiatives have been successful.
For more information: